LENSAR, Inc.
LNSRHealthcareNASDAQMedical Devices · Last scanned Oct 24, 2026
Scan Results
Daily timeframeLENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing laser systems for the treatment of cataracts and the management of pre-existing or surgically. The $74.6M market capitalization puts LNSR squarely in micro-cap range for its industry. The company offers the LENSAR Laser System, which incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes by providing imaging, procedure planning, design, and precision.
Market Cap
$74.6M
Beta
0.95
P/E (TTM)
33.72
P/E (Fwd)
-11.90
EPS (TTM)
$0.18
EPS (Fwd)
$-0.51
ROE
357.3%
ROA
-18.7%
Cash
$13.6M
Total Debt
$2.4M
Free CF
-$24.4M
52W Change
-49.3%
Annual Financials
Cash vs Debt
Where LNSR stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, LNSR finished 8.73% below its 150-day moving average ($6.30) and 25.42% below its 200-day moving average ($7.71). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is LNSR overbought or oversold?
At the October 20, 2026 close, LNSR's RSI(14) was 15.6, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $13.6M in cash comfortably exceeding the $2.4M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow is running at -$24.4M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at 357.3%, which is exceptionally high for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has grown from $35.4M (2022) to $58.4M (2025), reflecting a 65% increase over the period.
With cash comfortably exceeding debt, LNSR has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for LENSAR, Inc. and its sector.